• EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

  NCT05542355

  TerminatedInterventionalPhase 1Updated Oct 10, 2024
• Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

  NCT06306014

  RecruitingInterventionalPhase 1Phase 2Updated Aug 11, 2026
• Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group

  NCT03458195

  RecruitingInterventionalNot ApplicableUpdated Apr 24, 2026
• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy

  NCT05169593

  RecruitingInterventionalPhase 4Updated May 5, 2026
• Active Surgical Intervention on Crohn's Disease

  NCT05523050

  Unknown statusInterventionalNot ApplicableUpdated Aug 31, 2022
• A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

  NCT03943446

  TerminatedInterventionalPhase 2Updated Sep 7, 2023

ClinicalTrials.gov ID

NCT06925061

Lead Sponsor

Madeleine BezaultOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

80Estimated

Last Update Posted

Sep 17, 2025Actual

Start Date

Mar 31, 2025Actual

Primary Completion Date

Sep 13, 2026Estimated

Completion Date

Dec 31, 2026Estimated

Official Title

A Phase 2 Multicentre, Randomised, Parallel-arm, Placebo-controlled, Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

Brief Summary

MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, multicenter study of the impact of oral administration of EXL01 in the prevention of post-operative endoscopic recurrence of Crohn's disease after surgery.

Approximately 80 eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks or until a study or treatment discontinuation criterion is met. Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).

The primary objective is to compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo. Endoscopic recurrence will be assessed using the endoscopic score assessed by central reading at Week 24 after surgery. All participants will be followed for safety until 4 weeks after end of treatment.

Detailed Description

MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, multicenter study of the impact of oral administration of EXL01 in the prevention of post-operative endoscopic recurrence of Crohn's disease after surgery.

After surgery for Crohn's disease, as per institutional Standard of Care (SoC), approximately 80 eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks or until a study or treatment discontinuation criterion is met. Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).

The primary objective is to compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo.. All patients will be monitored continuously for safety while on the study treatment. Endoscopic recurrence will be assessed using the endoscopic score assessed by central reading at Week 24 after surgery. Faecal and blood samples for biomarker assessments will be obtained at Weeks 0, 4, 12, and 24. Patients who experience disease flare before Week 24 will discontinue the study treatment (EXL01 or placebo) and undergo an early discontinuation (ED) visit. All participants will be followed for safety until 4 weeks after end of treatment.

• Crohn Disease (CD)

• After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Is male or female aged ≥18 years at the time of providing documented informed consent.
• Has a diagnosis of CD with ileal involvement (ileal only or ileocolonic; L1 or L3 in Montreal classification) for at least 3 months prior to Screening.
• Has undergone an ileocecal resection or iterative ileo-colonic resection, as per institutional SoC, between 5 days to 5 weeks before randomization.
• Is scheduled, in SoC context, to receive no treatment for CD or anti-TNF agents in the 6 months after surgery

Exclusion Criteria:

• Has a not recovered adequately from any toxicity and/or complications from the surgery before the first dose of study intervention
• Has a current stoma. Inclusion will be possible after continuity restoration (during the 5 weeks following continuity restoration)
• Has active anal fistula
• Is scheduled, according to SoC, to receive a biotherapy at the exception of anti-TNF agent in the 6 months after surgery
• Has had more than 2 past small bowel resections or cumulated intestinal resection superior to 50 cm
• Has a contraindication to endoscopy or anaesthesia.
• Is receiving antibiotics at time of randomization or is likely to require antibiotic treatment within 6 weeks of the first dose of EXL01 or placebo.
• Has a history of hypersensitivity to EXL01 and/or any excipients, which are listed in the Investigator Brochure (IB), and/or to soybean or soy-containing products.
• Has a not recovered adequately from any toxicity and/or complications from the surgery before the first dose of study intervention
• Has a current stoma. Inclusion will be possible after continuity restoration (during the 5 weeks following continuity restoration)
• Has active anal fistula
• Is scheduled, according to SoC, to receive a biotherapy at the exception of anti-TNF agent in the 6 months after surgery
• Has had more than 2 past small bowel resections or cumulated intestinal resection superior to 50 cm
• Has a contraindication to endoscopy or anaesthesia.
• Is receiving antibiotics at time of randomization or is likely to require antibiotic treatment within 6 weeks of the first dose of EXL01 or placebo.
• Has a history of hypersensitivity to EXL01 and/or any excipients, which are listed in the Investigator Brochure (IB), and/or to soybean or soy-containing products.

Primary Purpose

Supportive Care

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Madeleine BezaultOTHER

pauline.wils@chru-lille.fr+33 03.20.44.59.62

caron.benedicte@hotmail.fr+33 03.83.15.76.41

arnaud.bourreille@chu-nantes.fr+33 (0)240 08 31 52

hebuterne.x@chu-nice.fr+33 (0)4 92 03 93 66